Volume 7, Number 6—December 2001
Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination
|Age (years)||No. HAa doses||No. OAEb||OAE reports/ 100,000 doses||RRR (95% CI)||No. SyAEc||SyAE reports/ 100,000 doses||RRR (95% CI)|
|45-64||1,096,391||23||2.10||0.7 (0.4-1.1)||26||2.37||1.0 (0.6-1.6)|
|75||61,760||1||1.62||0.5 (0.1-3.9)||3||4.86||1.9 (0.6-6.3)|
aHA = hepatitis A [vaccine]; CI = confidence intervals; OAE = other adverse events; SyAE = systemic adverse events; Ref = reference.
bUncomplicated neurologic/systemic, hypersensitivity, or local reaction.
cMultisystemic (excluding anaphylactic) or neurologic reaction.
1Jeff Altman, University of Washington, Seattle, Washington; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii; Elizabeth Barnett, Boston University, Boston, Massachusetts; Michele Barry Yale University, New Haven, Connecticut; Bradley Connor, Cornell University, New York, New York; David Freedman, University of Alabama at Birmingham, Birmingham, Alabama; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York; Elaine Jong, University of Washington, Seattle, Washington; Phyllis Kozarsky, Emory University, Atlanta, Georgia; Russell McMullen, University of Washington, Seattle, Washington; Jan Patterson, University of Texas, San Antonio, Texas; Bradley Sack, Johns Hopkins University, Baltimore, Maryland; Mary E. Wilson, Harvard University, Cambridge, Massachusetts; Martin Wolfe, Traveler's Medical Service of Washington, Washington, D.C.
- Page created: December 09, 2010
- Page last updated: December 09, 2010
- Page last reviewed: December 09, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)